Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$10.92 -1.3%	$11.70	$7.33 ▼ $21.00	$497.80M	1.04	492,421 shs	169,683 shs
LIVN LivaNova	$46.13 +0.1%	$43.64	$32.48 ▼ $57.35	$2.52B	0.9	638,315 shs	243,250 shs
NVCR NovoCure	$17.71 -1.0%	$17.70	$14.17 ▼ $34.13	$1.97B	0.72	1.13 million shs	534,101 shs
NVST Envista	$20.39 +1.1%	$18.26	$14.22 ▼ $23.00	$3.46B	1	2.50 million shs	1.00 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	0.00%	+4.00%	+1.11%	-32.68%	+42.56%
LIVN LivaNova	0.00%	+0.83%	+2.85%	+28.32%	-12.62%
NVCR NovoCure	0.00%	-1.64%	+7.63%	+7.37%	+4.95%
NVST Envista	0.00%	+3.58%	+9.12%	+31.80%	+25.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	2.033 of 5 stars	3.5	2.0	0.0	0.0	2.5	0.6
LIVN LivaNova	3.2245 of 5 stars	3.5	3.0	0.0	2.6	1.7	1.3
NVCR NovoCure	3.6008 of 5 stars	3.3	1.0	4.5	1.9	1.7	0.0
NVST Envista	3.667 of 5 stars	2.2	3.0	3.8	2.3	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$24.50	124.36% Upside
LIVN LivaNova	3.00	Buy	$59.29	28.52% Upside
NVCR NovoCure	2.67	Moderate Buy	$32.83	85.45% Upside
NVST Envista	2.33	Hold	$20.23	-0.78% Downside

Current Analyst Ratings Breakdown

Latest AXGN, NVST, NVCR, and LIVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$34.00
5/27/2025	NVST Envista	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/27/2025	NVST Envista	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$21.00 ➝ $23.00
5/20/2025	LIVN LivaNova	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$60.00
5/13/2025	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
5/13/2025	LIVN LivaNova	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00 ➝ $64.00
5/8/2025	LIVN LivaNova	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $55.00
5/8/2025	LIVN LivaNova	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$55.00 ➝ $61.00
5/5/2025	NVST Envista	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $18.00
5/2/2025	NVST Envista	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$21.00
4/30/2025	NVST Envista	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$187.34M	2.65	N/A	N/A	$2.36 per share	4.63
LIVN LivaNova	$1.28B	1.97	$4.24 per share	10.88	$24.31 per share	1.90
NVCR NovoCure	$621.71M	3.17	N/A	N/A	$3.33 per share	5.32
NVST Envista	$2.51B	1.38	$1.66 per share	12.27	$17.05 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$9.96M	-$0.15	N/A	N/A	N/A	-3.68%	-7.09%	-3.67%	8/6/2025 (Estimated)
LIVN LivaNova	$63.23M	-$4.09	N/A	14.69	N/A	-17.41%	13.67%	6.68%	7/30/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)
NVST Envista	-$1.12B	-$6.53	N/A	16.85	1.30	-44.90%	4.07%	2.25%	8/6/2025 (Estimated)

Latest AXGN, NVST, NVCR, and LIVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	LIVN LivaNova	$0.84	N/A	N/A	N/A	$332.20 million	N/A
7/24/2025	Q2 2025	NVCR NovoCure	-$0.40	N/A	N/A	N/A	$153.87 million	N/A
5/1/2025	Q1 2025	NVST Envista	$0.20	$0.24	+$0.04	$0.10	$608.17 million	$616.90 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
LIVN LivaNova	N/A	N/A	N/A	N/A	N/A
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
NVST Envista	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.63	4.28	2.65
LIVN LivaNova	0.53	1.58	1.37
NVCR NovoCure	0.27	1.47	1.41
NVST Envista	0.43	2.12	1.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
LIVN LivaNova	97.64%
NVCR NovoCure	84.61%
NVST Envista	N/A

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
LIVN LivaNova	0.29%
NVCR NovoCure	5.52%
NVST Envista	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	45.54 million	44.28 million	Optionable
LIVN LivaNova	2,900	54.53 million	54.37 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable
NVST Envista	12,300	169.49 million	167.28 million	Optionable

AXGN, NVST, NVCR, and LIVN Headlines

Recent News About These Companies

Lightrock Netherlands B.V. Has $8.03 Million Stock Position in Envista Holdings Corporation (NYSE:NVST)

July 5 at 7:16 AM | marketbeat.com

Leeward Investments LLC MA Sells 20,728 Shares of Envista Holdings Corporation (NYSE:NVST)

July 4 at 6:34 AM | marketbeat.com

Envista Holdings Corporation (NVST) - Yahoo Finance

July 4 at 2:23 AM | finance.yahoo.com

Envista Holdings Corporation (NYSE:NVST) Shares Bought by Wealth Enhancement Advisory Services LLC

July 3 at 3:16 AM | marketbeat.com

Envista (NVST) and The Competition Head to Head Analysis

July 2, 2025 | americanbankingnews.com

Marathon Asset Management Ltd Has $16.63 Million Stock Position in Envista Holdings Corporation (NYSE:NVST)

June 28, 2025 | marketbeat.com

5 Must-Read Analyst Questions From Envista’s Q1 Earnings Call

June 27, 2025 | msn.com

NVST vs. ABT: Which Stock Is the Better Value Option?

June 26, 2025 | zacks.com

Why Envista Holdings Corporation (NYSE:NVST) Could Be Worth Watching

June 25, 2025 | finance.yahoo.com

Envista Holdings Shows Rising Relative Strength; Still Shy Of Key Benchmark

June 23, 2025 | msn.com

Envista Holdings Corporation (NYSE:NVST) Receives Consensus Recommendation of "Hold" from Analysts

June 23, 2025 | marketbeat.com

Should You Add NVST Stock to Your Portfolio Right Now?

June 19, 2025 | zacks.com

GAMMA Investing LLC Raises Stock Holdings in Envista Holdings Corporation (NYSE:NVST)

June 19, 2025 | marketbeat.com

Envista Holdings Co. (NYSE:NVST) Shares Acquired by SG Americas Securities LLC

June 16, 2025 | marketbeat.com

1 Cash-Producing Stock with Exciting Potential and 2 to Turn Down

June 12, 2025 | msn.com

Envista Holdings Co. (NYSE:NVST) Shares Sold by Wedge Capital Management L L P NC

June 12, 2025 | marketbeat.com

All You Need to Know About Envista (NVST) Rating Upgrade to Buy

June 10, 2025 | zacks.com

NVST vs. ABT: Which Stock Should Value Investors Buy Now?

June 10, 2025 | zacks.com

3 Reasons to Sell NVST and 1 Stock to Buy Instead

June 9, 2025 | msn.com

Baird Upgrades Envista Holdings (NVST) Stock to Outperform, Raises PT

May 29, 2025 | msn.com

Baird Upgrades Envista Holdings (NVST)

May 28, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN, NVST, NVCR, and LIVN Company Descriptions

AxoGen NASDAQ:AXGN

$10.92 -0.14 (-1.27%)

As of 07/3/2025 01:04 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

LivaNova NASDAQ:LIVN

$46.13 +0.05 (+0.11%)

Closing price 07/3/2025 01:00 PM Eastern

Extended Trading

$46.10 -0.03 (-0.07%)

As of 07/3/2025 04:08 PM Eastern

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

NovoCure NASDAQ:NVCR

$17.70 -0.18 (-0.98%)

As of 07/3/2025 03:48 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Envista NYSE:NVST

$20.39 +0.22 (+1.09%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$20.42 +0.03 (+0.15%)

As of 07/3/2025 04:46 PM Eastern

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time